Table 1 Baseline characteristics of the study participants
From: Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma
No. | Gender | Age | Myeloma isotype | Vaccination dose level |
|---|---|---|---|---|
1 | M | 62 | λ-light chain | 0.25 mg |
2 | M | 58 | IgA1-κ/light chain | 0.25 mg |
3 | M | 56 | IgG1-λ | 0.25 mg |
4 | F | 69 | IgG1-λ | 0.25 mg |
5 | F | 59 | IgG1-λ | 0.25 mg |
6 | F | 62 | IgG1-κ | 1.25 mg |
7 | F | 50 | IgG1-κ | 1.25 mg |
8 | M | 59 | IgG1-κ | 1.25 mg |
9 | M | 57 | IgG1-κ | 1.25 mg |
10 | M | 63 | IgG1-λ | 1.25 mg |
11 | M | 52 | IgG1-κ | 2.5 mg |
12 | M | 62 | κ-light chain | 2.5 mg |
13 | M | 63 | IgG1-κ | 2.5 mg |
14 | F | 60 | IgG1-κ | 2.5 mg |
15 | M | 66 | IgG1-κ | 2.5 mg |